annual cash & cash equivalents:
$11.46B-$1.93B(-14.44%)Summary
- As of today (May 20, 2025), NVS annual cash & cash equivalents is $11.46 billion, with the most recent change of -$1.93 billion (-14.44%) on December 31, 2024.
- During the last 3 years, NVS annual cash & cash equivalents has fallen by -$948.00 million (-7.64%).
- NVS annual cash & cash equivalents is now -14.44% below its all-time high of $13.39 billion, reached on December 31, 2023.
Performance
NVS Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$7.07B-$4.39B(-38.34%)Summary
- As of today (May 20, 2025), NVS quarterly cash & cash equivalents is $7.07 billion, with the most recent change of -$4.39 billion (-38.34%) on March 31, 2025.
- Over the past year, NVS quarterly cash & cash equivalents has dropped by -$2.40 billion (-25.38%).
- NVS quarterly cash & cash equivalents is now -56.38% below its all-time high of $16.20 billion, reached on June 30, 2008.
Performance
NVS quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVS Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -14.4% | -25.4% |
| 3 y3 years | -7.6% | -49.0% |
| 5 y5 years | +3.1% | +56.0% |
NVS Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -14.4% | +52.4% | -49.0% | +94.9% |
| 5 y | 5-year | -14.4% | +52.4% | -49.0% | +94.9% |
| alltime | all time | -14.4% | +462.3% | -56.4% | +246.7% |
NVS Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $7.07B(-38.3%) |
| Dec 2024 | $11.46B(-14.4%) | $11.46B(-15.8%) |
| Sep 2024 | - | $13.61B(+72.2%) |
| Jun 2024 | - | $7.90B(-16.5%) |
| Mar 2024 | - | $9.47B(-29.3%) |
| Dec 2023 | $13.39B(+78.2%) | $13.39B(+8.0%) |
| Sep 2023 | - | $12.40B(+14.0%) |
| Jun 2023 | - | $10.88B(-9.3%) |
| Mar 2023 | - | $12.00B(+59.6%) |
| Dec 2022 | $7.52B(-39.4%) | $7.52B(-13.9%) |
| Sep 2022 | - | $8.73B(+140.7%) |
| Jun 2022 | - | $3.63B(-73.8%) |
| Mar 2022 | - | $13.85B(+11.6%) |
| Dec 2021 | $12.41B(+28.5%) | $12.41B(+72.1%) |
| Sep 2021 | - | $7.21B(+40.9%) |
| Jun 2021 | - | $5.12B(+34.6%) |
| Mar 2021 | - | $3.80B(-60.6%) |
| Dec 2020 | $9.66B(-13.1%) | $9.66B(+7.4%) |
| Sep 2020 | - | $8.99B(+52.0%) |
| Jun 2020 | - | $5.92B(+30.7%) |
| Mar 2020 | - | $4.53B(-59.3%) |
| Dec 2019 | $11.11B(-16.3%) | $11.11B(+32.6%) |
| Sep 2019 | - | $8.38B(-16.1%) |
| Jun 2019 | - | $9.99B(+46.8%) |
| Mar 2019 | - | $6.81B(-48.7%) |
| Dec 2018 | $13.27B(+49.8%) | $13.27B(-5.2%) |
| Sep 2018 | - | $14.00B(+12.5%) |
| Jun 2018 | - | $12.45B(+114.1%) |
| Mar 2018 | - | $5.81B(-34.4%) |
| Dec 2017 | $8.86B(+26.4%) | $8.86B(+26.4%) |
| Dec 2016 | $7.01B(+49.9%) | $7.01B(+49.9%) |
| Dec 2015 | $4.67B(-64.1%) | $4.67B(-64.1%) |
| Dec 2014 | $13.02B(+94.8%) | $13.02B(+94.8%) |
| Dec 2013 | $6.69B(+20.4%) | $6.69B(+20.4%) |
| Dec 2012 | $5.55B(+49.7%) | $5.55B(+49.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $3.71B(-30.3%) | $3.71B(-30.3%) |
| Dec 2010 | $5.32B(+83.8%) | $5.32B(+83.8%) |
| Dec 2009 | $2.89B(+42.0%) | $2.89B(+42.0%) |
| Dec 2008 | $2.04B(-62.0%) | $2.04B(-75.0%) |
| Sep 2008 | - | $8.14B(-49.8%) |
| Jun 2008 | - | $16.20B(+49.3%) |
| Mar 2008 | - | $10.85B(+102.4%) |
| Dec 2007 | $5.36B(+40.5%) | $5.36B(-63.1%) |
| Sep 2007 | - | $14.53B(+92.5%) |
| Jun 2007 | - | $7.55B(+8.5%) |
| Mar 2007 | - | $6.96B(+82.4%) |
| Dec 2006 | $3.81B(-39.6%) | $3.81B(-55.3%) |
| Sep 2006 | - | $8.53B(+16.7%) |
| Jun 2006 | - | $7.31B(-34.2%) |
| Mar 2006 | - | $11.12B(+75.9%) |
| Dec 2005 | $6.32B(+3.9%) | $6.32B(-20.5%) |
| Sep 2005 | - | $7.95B(-15.8%) |
| Jun 2005 | - | $9.44B(-23.1%) |
| Mar 2005 | - | $12.28B(+101.9%) |
| Dec 2004 | $6.08B(+7.7%) | $6.08B(+91.3%) |
| Sep 2004 | - | $3.18B(-10.9%) |
| Jun 2004 | - | $3.57B(+9.9%) |
| Mar 2004 | - | $3.25B(-42.5%) |
| Dec 2003 | $5.65B(-2.6%) | $5.65B(+20.5%) |
| Sep 2003 | - | $4.68B(+2.9%) |
| Jun 2003 | - | $4.55B(-23.8%) |
| Mar 2003 | - | $5.97B(+3.0%) |
| Dec 2002 | $5.80B(-13.8%) | $5.80B(-43.9%) |
| Sep 2002 | - | $10.33B(-19.9%) |
| Jun 2002 | - | $12.90B(+91.8%) |
| Dec 2001 | $6.73B(+23.3%) | $6.73B(+155.0%) |
| Jun 2001 | - | $2.64B(-51.6%) |
| Dec 2000 | $5.45B(+38.3%) | $5.45B(+59.5%) |
| Jun 2000 | - | $3.42B |
| Dec 1999 | $3.94B(-18.4%) | - |
| Dec 1998 | $4.83B | - |
FAQ
- What is Novartis AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novartis AG?
- What is Novartis AG annual cash & cash equivalents year-on-year change?
- What is Novartis AG quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Novartis AG?
- What is Novartis AG quarterly cash & cash equivalents year-on-year change?
What is Novartis AG annual cash & cash equivalents?
The current annual cash & cash equivalents of NVS is $11.46B
What is the all time high annual cash & cash equivalents for Novartis AG?
Novartis AG all-time high annual cash & cash equivalents is $13.39B
What is Novartis AG annual cash & cash equivalents year-on-year change?
Over the past year, NVS annual cash & cash equivalents has changed by -$1.93B (-14.44%)
What is Novartis AG quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NVS is $7.07B
What is the all time high quarterly cash & cash equivalents for Novartis AG?
Novartis AG all-time high quarterly cash & cash equivalents is $16.20B
What is Novartis AG quarterly cash & cash equivalents year-on-year change?
Over the past year, NVS quarterly cash & cash equivalents has changed by -$2.40B (-25.38%)